BioSpace News Archive

PolarityTE, Inc. a biotechnology company developing regenerative tissue products and biomaterials, provided a business update and reported financial results for the three and nine-month periods ended September 30, 2021.

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), today announced a poster presentation at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), being held virtually November 12-15, 2021.

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today that it has been informed by the Israeli Innovation Authority (IIA) of the IIA’s decision to fund a second 18-month period of the CRISPR-IL consortium established last year.

Theseus Pharmaceuticals, Inc. announced that Tim Clackson, Ph.D., President and Chief Executive Officer of Theseus, will participate in a virtual fireside chat for the 12th Annual Jefferies London Healthcare Conference, taking place November 16-19, 2021.

Sutro Biopharma, Inc. (NASDAQ: STRO), today reported its financial results for the quarter ended September 30, 2021, its recent business highlights, and a preview of anticipated select milestones in the remainder of 2021.

AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, announced that members of its senior management team will participate in two upcoming virtual investor conferences.

BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will participate in fireside chats at two upcoming healthcare investor conferences.

Xeris Biopharma Holdings, Inc. today announced financial results for the third quarter and first nine months ended September 30, 2021, and recent highlights, including the completion of the Strongbridge Biopharma plc acquisition on October 5, 2021.

4E Therapeutics, Inc. announced that it has been awarded a $5.5 million Phase 2 National Institutes of Health (NIH) Small Business Innovation Research (SBIR) UG3 grant as part of the NIH Helping to End Addiction Long-Term (HEAL) Initiative.

Vera Therapeutics, Inc. today reported its business highlights and financial results for the quarter ending September 30, 2021, and provided a corporate update.